Gonax 240mg for Subcutaneous Injection (ゴナックス皮下注用240mg)

Country: Japan

Language: English

Source: すりの適正使用協議会 RAD-AR Council, Japan

Buy It Now

Active ingredient:

Degarelix acetate

Available from:

Ferring Pharmaceuticals Co., Ltd.

INN (International Name):

Degarelix acetate

Pharmaceutical form:

injection

Patient Information leaflet

                                Drug Information Sheet("Kusuri-no-Shiori")
Injection
Published: 01/2022
The information on this sheet is based on approvals granted by the
Japanese regulatory authority. Approval
details may vary by country. Medicines have adverse reactions (risks)
as well as efficacies (benefits). It is
important to minimize adverse reactions and maximize efficacy. To
obtain a better therapeutic response,
patients should understand their medication and cooperate with the
treatment.
BRAND NAME:
GONAX 240MG FOR SUBCUTANEOUS INJECTION
ACTIVE INGREDIENT:
Degarelix acetate
DOSAGE FORM:
injection
IMPRINT OR PRINT ON WRAPPING:
EFFECTS OF THIS MEDICINE
This medicine contains GnRH (gonadotropin-releasing hormone)
antagonist as an active
ingredient. It inhibits testicular testosterone secretion by
suppressing the action of GnRH in
the pituitary gland, thereby reduces cancer cell proliferation in the
prostate.
It is usually used to treat prostate cancer.
THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS
MEDICINE.BE SURE TO TELL YOUR DOCTOR
AND PHARMACIST.
・If you have previously experienced any allergic reactions (itching,
rash, etc.) to any
medicines or foods.
If you have or have a history of interstitial lung disease.
・If you are taking any other medicinal products. (Some medicines may
interact to enhance or
diminish medicinal effects. Beware of over-the-counter medicines and
dietary supplements
as well as other prescription medicines.)
DOSING SCHEDULE (HOW TO TAKE THIS MEDICINE)
・
Your dosing schedule prescribed by your doctor is((         
           
to be written by a healthcare
professional
))
・In general, inject the first dose of this medicine subcutaneously
at two points into the
abdomen. The second dose must be given 4 weeks after the initial dose.
Beginning from the
second dose, inject this medicine subcutaneously at one point on the
abdomen every 4
weeks, or at two points on the abdomen every 12 weeks.
・Ask the doctor about the treatment period.
PRECAUTIONS WHILE TAKING THIS MEDICINE

                                
                                Read the complete document
                                
                            

Search alerts related to this product